Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC)

Bristol-Myers Squibb (BMS)

Status and phase: Completed; Phase 2

Conditions: Non-Small Cell Lung Cancer

Treatments: Drug: Paclitaxel

Study type: Interventional

Funder types: Industry

Identifiers

NCT01024062

CA139-373

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy and the safety of paclitaxel given weekly in patients with advanced or recurrent non-small cell lung cancer

Enrollment: 60 estimated patients

Sex: All

Ages: 20 to 74 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with no prior chemotherapy who meet either of the listed below:
• Patient with stage IIIB or IV disease
• Patients with recurrent disease following potentially curative surgical resection
• Patients with previous chemotherapy up to one regimen

Exclusion criteria

• Patients with serious, uncontrolled medical illness
• Patients with previous therapy with taxanes

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

60 participants in 1 patient group

Paclitaxel

Experimental group

Treatment:

Drug: Paclitaxel